Caspofungin

證據等級: L5

預測適應症: 10 個

Caspofungin: From Invasive Candidiasis to Gastrin Secretion Abnormality

One-Sentence Summary

Caspofungin is an echinocandin-class antifungal agent with established clinical use in invasive candidiasis and invasive aspergillosis, currently not registered in India. The TxGNN model ranks Gastrin Secretion Abnormality as its top predicted new indication, with 0 clinical trials and 0 publications directly supporting this direction — suggesting a probable false positive from the knowledge graph.

Quick Overview

Item	Content
Original Indication	Invasive candidiasis; invasive aspergillosis (known clinical use; no India registration on record)
Predicted New Indication	Gastrin Secretion Abnormality
TxGNN Prediction Score	99.44%
Evidence Level	L5
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on information embedded in the evidence pack’s repurposing rationale, Caspofungin belongs to the echinocandin class and exerts its antifungal effect by inhibiting β-1,3-glucan synthase (encoded by FKS1 and FKS2 genes) — an enzyme essential for fungal cell wall biosynthesis. Disruption of the cell wall leads to osmotic instability and fungal cell death. Its efficacy in invasive Candida and Aspergillus infections is well-established in international guidelines.

Gastrin secretion abnormality involves dysregulation of gastrin production by G cells in the gastric antrum, modulated through CCK-B (cholecystokinin B) receptors and neuroendocrine signalling. There is no known pharmacological bridge between β-1,3-glucan synthesis inhibition and this neuroendocrine pathway.

The TxGNN model’s high score (99.44%) for this indication most likely reflects a distant indirect node connection in the knowledge graph — e.g., the path: Candida infection → gut microbiome disruption → gastrointestinal hormone dysregulation → gastrin abnormality. This is a low-specificity, multi-hop inference rather than a mechanistically grounded prediction, and carries a high probability of being a false positive. No preclinical or clinical data exists to elevate this beyond an algorithm-generated hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Drug Interactions (81 total interactions identified; selected highlights shown below):

Interacting Drug	Severity
Dexamethasone	Major
Naltrexone	Moderate
Calcitriol	Unknown
Pantoprazole	Unknown
Doxycycline	Unknown
Morphine	Unknown
Omeprazole	Unknown
Lansoprazole	Unknown
Vancomycin	Unknown
Sucralfate	Unknown
Lactulose	Unknown
Prednisone	Unknown
Simvastatin	Unknown
Nystatin	Unknown
Epinephrine	Unknown
Amphotericin B	Unknown
Hydrocortisone	Unknown
Prednisolone	Unknown

The Major interaction with Dexamethasone is the most clinically significant finding. Caspofungin’s plasma levels can be reduced by enzyme inducers; co-administration with systemic corticosteroids warrants dose review. The high count of Unknown-severity interactions (largely with common ICU medications — PPIs, corticosteroids, opioids, antibiotics) reflects incomplete DDI characterisation and should be evaluated systematically before any new indication study is designed.

For complete warnings and contraindications, please refer to the originator package insert (Cancidas® / Merck), as formal CDSCO labelling data was not available in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no identified mechanistic link between caspofungin’s β-1,3-glucan synthase inhibition and gastrin secretion pathways, and a complete absence of supporting clinical trials or literature makes this indication unsuitable for further development at this stage. The high TxGNN score most likely reflects knowledge-graph topology rather than true pharmacological relevance.

To proceed with this specific indication, the following would be needed:

A plausible biological hypothesis connecting the echinocandin mechanism to G-cell / CCK-B receptor biology (e.g., via fungal-gut microbiome-gastrin axis)
Preclinical evidence (in vitro or in vivo) demonstrating any effect on gastrin secretion
Retrieval of full MOA data from DrugBank (DB00520) and CDSCO / originator package insert

⚠️ Note on higher-priority indications in this evidence pack:

While the top-ranked TxGNN prediction (Gastrin Secretion Abnormality, Rank 1) is a Hold, two additional indications within this same evidence pack carry meaningfully stronger evidence and merit separate evaluation:

Rank	Indication	Evidence Level	Decision
8	Candida glabrata infection	L2	Proceed with Guardrails
9	Neonatal Candidiasis	L2	Research Question
10	Congenital Candidiasis	L2	Proceed with Guardrails

Caspofungin is an IDSA-recommended first-line agent for invasive C. glabrata infections, with Phase 4 clinical trial data (NCT00839540), pharmacokinetic studies in neonates (NCT00330395), and a completed Phase 3 trial in Chinese adults supporting the congenital/neonatal candidiasis use case (NCT00635648). These indications represent the most clinically actionable repurposing opportunities in this evidence pack and should be prioritised for full report generation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.